PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.

ABSTRACT: Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.

SUBMITTER: Hartkopf AD 

PROVIDER: S-EPMC5290437 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature